Clinical Trial Update: Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial of LN-144 in combination with pembrolizumab for high-risk resectable stage III melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• LN-144
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: James Isaacs, MD | Conditions: Stage IIIB Melanoma, Stage IIIC Melanoma | Phase 1 | Status: WITHDRAWN